Clinical Trial

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2024 (before its estimated October 17, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-11-11; most recent amendment 2024-10-11.
Status change: Recruiting → Active, Not Recruiting 2024-10-11
Trial Details
NCT Number NCT05620134
Lead Sponsor Salubris Biotherapeutics Inc
Conditions Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Melanoma, Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer +14 more
Enrollment 263 participants
Start Date 2022-10-17
Primary Completion 2025-10-17 (estimated)
Study Completion 2026-02-20 (estimated)
Updated on ClinicalTrials.gov 2024-10-15